$1.06 Billion in Sales Expected for Alexion Pharmaceuticals, Inc. (ALXN) This Quarter

Share on StockTwits

Analysts forecast that Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) will report sales of $1.06 billion for the current quarter, Zacks Investment Research reports. Eight analysts have provided estimates for Alexion Pharmaceuticals’ earnings, with estimates ranging from $1.04 billion to $1.13 billion. Alexion Pharmaceuticals posted sales of $909.70 million during the same quarter last year, which would indicate a positive year over year growth rate of 16.5%. The firm is scheduled to report its next earnings report on Thursday, February 14th.

On average, analysts expect that Alexion Pharmaceuticals will report full year sales of $4.07 billion for the current fiscal year, with estimates ranging from $4.04 billion to $4.13 billion. For the next fiscal year, analysts expect that the firm will report sales of $4.76 billion, with estimates ranging from $4.50 billion to $4.92 billion. Zacks’ sales calculations are a mean average based on a survey of sell-side research firms that cover Alexion Pharmaceuticals.

Alexion Pharmaceuticals (NASDAQ:ALXN) last announced its quarterly earnings results on Wednesday, October 24th. The biopharmaceutical company reported $2.02 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.74 by $0.28. Alexion Pharmaceuticals had a net margin of 3.90% and a return on equity of 16.60%. The firm had revenue of $1.03 billion during the quarter, compared to the consensus estimate of $1.02 billion. During the same period last year, the firm earned $1.44 EPS. The business’s quarterly revenue was up 19.5% compared to the same quarter last year.

ALXN has been the subject of several analyst reports. BidaskClub downgraded shares of Alexion Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, October 9th. Barclays raised their price target on shares of Alexion Pharmaceuticals to $175.00 and gave the company an “overweight” rating in a report on Friday, September 28th. ValuEngine raised shares of Alexion Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Thursday, November 8th. Zacks Investment Research downgraded shares of Alexion Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Monday, August 13th. Finally, Morgan Stanley raised their price target on shares of Alexion Pharmaceuticals from $157.00 to $165.00 and gave the company an “overweight” rating in a report on Thursday, October 11th. Three analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has issued a strong buy rating to the company. The stock has a consensus rating of “Buy” and an average target price of $161.50.

In related news, EVP Indrani Lall Franchini sold 2,605 shares of Alexion Pharmaceuticals stock in a transaction on Wednesday, November 28th. The shares were sold at an average price of $118.13, for a total value of $307,728.65. Following the transaction, the executive vice president now owns 29,304 shares in the company, valued at approximately $3,461,681.52. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 4.35% of the stock is owned by company insiders.

A number of large investors have recently modified their holdings of the stock. Rehmann Capital Advisory Group increased its position in shares of Alexion Pharmaceuticals by 10.7% in the third quarter. Rehmann Capital Advisory Group now owns 2,933 shares of the biopharmaceutical company’s stock valued at $408,000 after acquiring an additional 283 shares during the period. MARSHALL WACE ASIA Ltd purchased a new position in shares of Alexion Pharmaceuticals in the third quarter valued at about $4,939,000. Clearbridge Investments LLC increased its position in shares of Alexion Pharmaceuticals by 15.4% in the third quarter. Clearbridge Investments LLC now owns 5,178,157 shares of the biopharmaceutical company’s stock valued at $719,816,000 after acquiring an additional 691,390 shares during the period. Vanguard Group Inc. increased its position in shares of Alexion Pharmaceuticals by 1.2% in the third quarter. Vanguard Group Inc. now owns 15,811,291 shares of the biopharmaceutical company’s stock valued at $2,197,928,000 after acquiring an additional 192,857 shares during the period. Finally, Morgan Stanley increased its position in shares of Alexion Pharmaceuticals by 2.1% in the third quarter. Morgan Stanley now owns 781,891 shares of the biopharmaceutical company’s stock valued at $108,691,000 after acquiring an additional 16,017 shares during the period. Institutional investors own 93.33% of the company’s stock.

NASDAQ:ALXN traded down $5.44 during trading hours on Monday, hitting $115.60. The stock had a trading volume of 1,229,654 shares, compared to its average volume of 1,105,094. The company has a debt-to-equity ratio of 0.32, a current ratio of 3.16 and a quick ratio of 2.74. Alexion Pharmaceuticals has a one year low of $102.10 and a one year high of $140.77. The company has a market cap of $27.00 billion, a price-to-earnings ratio of 22.40, a PEG ratio of 1.04 and a beta of 1.02.

Alexion Pharmaceuticals Company Profile

Alexion Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes various therapeutic products. The company offers Soliris (eculizumab), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; atypical hemolytic uremic syndrome (aHUS), a genetic disease; and generalized myasthenia gravis, a debilitating, complement-mediated neuromuscular disease.

Further Reading: How are Outstanding Shares Different from Authorized Shares?

Get a free copy of the Zacks research report on Alexion Pharmaceuticals (ALXN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply